Angiogenesis as a target for cancer therapy

This publication has 98 references indexed in Scilit:

• A phase II study of Erbitux (IMC-C225), an Epidermal Growth Factor Receptor (EGFR) blocking ntibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced Non-Small Cell Lung Cancer (NSCLC)
  European Journal Of Cancer, 2002
• VEGF₁₆₅ mediates formation of complexes containing VEGFR‐2 and neuropilin‐1 that enhance VEGF₁₆₅‐receptor binding
  Journal of Cellular Biochemistry, 2002
• Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins
  Nature Medicine, 2002
• Signals via FGF Receptor 2 Regulate Migration of Endothelial Cells
  Biochemical and Biophysical Research Communications, 2001
• The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization
  Oncogene, 2000
• The Hallmarks of Cancer
  Cell, 2000
• Extensive Vasculogenesis, Angiogenesis, and Organogenesis Precede Lethality in Mice Lacking All αv Integrins
  Cell, 1998
• Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
  Published by Elsevier ,1996
• Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
  Nature, 1996
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
  Nature, 1993